-
Sector Analysis
Diabetic Macular Edema (DME): Epidemiology Forecast to 2034
Diabetic macular edema (DME) is a vision-threatening complication of diabetes that is a major cause of vision impairment in diabetic individuals and is characterized by fluid accumulation in the macula due to a breakdown of the blood retinal barrier (BRB) (Cheema and Cheema, 2024). DME manifests as retinal thickening caused by the accumulation of intraretinal fluid, primarily in the inner and outer plexiform layers. It can occur due to hyperpermeability of the retinal vasculature. DME can occur with any level...
-
Sector Analysis
Insomnia: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2032
Understand the Future of the Insomnia Therapeutics Market The insomnia therapeutics market continues to evolve as treatment innovation, unmet patient needs, and changing prescribing patterns reshape the competitive landscape. This report provides a comprehensive analysis of the insomnia market across the 7MM, supported by an Excel-based forecast model covering the period from 2022 to 2032. Z-drugs remain the most common first-line treatment across the US and 5EU markets, while the current pipeline remains limited but diverse, featuring products with varying...
-
Sector Analysis
Bipolar Disorder: Opportunity Assessment, Epidemiology, Disease Management, and Forecast to 2034
This report covers the 7MM and provides an Excel-based forecast model for the Bipolar Disorder market through 2034. The bipolar disorder market is crowded with inexpensive generic products and off-label drugs.There are currently not many effective treatments targeting bipolar depression, warranting targeted drug development. In the late-stage pipeline (Phase IIb onwards), there are four products being developed to target the depressive polarity of bipolar disorder. The BD market across the 7MM was valued at $5.6 billion in the 2024 baseline...
-
Thematic Analysis
Cell and Gene Therapy Investment Trends: Strategic Intelligence
Report Value Proposition – Why Does the Cell & Gene Therapy Investment Landscape Matter? Cell and gene therapies (CGTs) are transforming the treatment of genetic diseases, oncology, hematological disorders, and neurological conditions, creating one of the most dynamic areas of biopharmaceutical innovation. As the market matures, investors are shifting their focus toward scalable technologies, manufacturing capabilities, platform innovation, and commercially viable therapeutic programs. GlobalData's Cell & Gene Therapy Investment Trends report provides a comprehensive analysis of the evolving CGT investment...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, December 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, November 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Thematic Analysis
FDI Trends in the Middle East (2025)
Following a period of significant Foreign Direct Investment (FDI) growth from 2019 to 2023, the inflow of FDI into the Middle East (ME) has slowed down due to risk premiums affecting investor confidence. Capital market reforms, eased equity caps, and limited FDI screening adopted by the likes of Saudi Arabia and the UAE have made material differences to making nations more compatible with global markets. Still, FDI projects opened in the ME region declined by 10.6% YoY in 2024, according...
-
Sector Analysis
Chronic Hepatitis B Therapeutics Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
The report provides an in-depth assessment of the CHB therapeutics market including disease overview, epidemiology, disease management, current treatment options, unmet needs and opportunities, R&D strategies, pipeline assessment, current and future players, and market outlook. The hepatitis B virus (HBV) is a member of the Orthohepadnavirus genus, from the Hepadnaviridae family. HBV is transmitted through infected blood and body fluids, most commonly through unprotected sex and contaminated needles. HBV can also be transmitted from mother to child at birth, which...
-
Sector Analysis
Healthcare Financing Reform in Latvia: a Battle for the Bare Minimum
A new draft amendment of Latvia's Healthcare Financing Law was approved recently by the government, that once again shelves proposals to switch from the current general taxation-funded public healthcare model to a health insurance-based system; this is the latest in a long series of postponements to a change in the public healthcare financing model that is thought would allow for an expansion of the funding base and a much needed boost in the funding of the public healthcare system. GlobalData...
-
Sector Analysis
A Closer Look at the HTA Landscape in Oman, Saudi Arabia, and the UAE
Healthcare systems in the Gulf Cooperation Council (GCC)—comprised of Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates (UAE)—are the most developed in the Middle East region. Driven by rapid population growth, the GCC governments have made—and continue to make—significant investments for transformation in the healthcare sector, while simultaneously introducing cost-containment measures to control healthcare spending. As the value of reimbursed health technologies increases, the governments are increasingly becoming more reliant on economic evaluations or health technology assessments...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.